Investigational New Drug (IND) Allowance

DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ — DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate…